RecruitMe Clinical Trial

A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Study for patients with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma using study drug pembrolizumab
Sponsor:Merck
Enrolling:Male and Female Patients
Age Range:Between 18 and 99 years old
IRB Number:AAAO8259
U.S. Government ID:NCT02335411
Contact: Gulam Manji, MD: 646-317-6085 / gam2140@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to assess the safety, tolerablility, and effectiveness of pembrolizumab alone or in combination with standard treatment (cisplatin and 5-fluorouracil) for recurrent or metastatic Gastric Cancer or Gastroesophageal Junction Cancer. Participants will be in the study for approximately 24 months.

This study is closed
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Gulam Manji, MD
Email: gam2140@cumc.columbia.edu
Phone: 646-317-6085